In this week's EuroBiotech Report, the last week of July was a massive one for European biotech IPOs, with BioBlast Pharma, Innocoll, Macrocure, Mapi Pharma and VBL Therapeutics all heading to the Nasdaq. All of the companies struggled though. And more.
The FDA approved Boehringer Ingelheim's COPD treatment Striverdi Respimat, a once-a-day inhaler the German drugmaker hopes can contend in a crowded respiratory market.
California biotech Cold Genesys has wrapped up a $13.6 million A round to support its work on cancer treatment that promises to infect tumor cells and convince the immune system to join the fight.
The FDA's Janet Woodcock may be Sarepta CEO Chris Garabedian's favorite person today.
AstraZeneca's internal forecast for a bright future is heavily dependent on a cache of new cancer immunotherapies, and the U.K. drugmaker is planning to test its lead oncology treatment in more and more tumor types with hopes of delivering on a $6.5 billion peak sales estimate.
Analysts at Silicon Valley Bank have been crunching the numbers on biotech investing, and they have found that a group of busy corporate venture arms has fundamentally changed the landscape for startups and the entire field of early-state drug development--with some big implications for the current crop of industry upstarts.
Menlo Park, CA's Avalanche Biotechnologies pulled off a $102 million Wall Street debut, planning to spend its new cash on a pipeline of gene therapies for ocular diseases.
Sanofi and Regeneron just stole a march on Amgen in the race to get their PCSK9 cardio drug through the FDA and onto the market. The two companies revealed Wednesday evening that they had picked up a priority review voucher BioMarin had won for a recent rare disease drug approval, paying $67.5 million for the regulatory shortcut. They'll split the cost and share in the benefit, shaving four months off the regulatory review time for alirocumab.
Gilead has picked up the exclusive rights to develop a set of HIV-neutralizing antibodies discovered at Theraclone in collaboration with the International AIDS Vaccine Initiative and The Scripps Research Institute. Seattle-based Theraclone, which used its tech platform I-STAR in the project, picked up an unspecified set of milestones and an upfront payment in the deal.
Sanofi and Regeneron are heading to the FDA with a potential blockbuster cardiovascular treatment, touting positive results from a slew of Phase III trials in which the drug slashed patients' bad cholesterol.
Demonstrating yet again that AstraZeneca sees a big future for itself in the hot immuno-oncology field, the pharma giant today unveiled another collaboration on a combo for MEDI-4736, its anti-PD-L1 therapy looking to suit up for some blockbuster competition in treating cancer. Japan's Kyowa Hakko Kirin is matching its anti-CCR4 antibody, mogamulizumab, with AstraZeneca's MEDI-4736 to gauge its efficacy and safety in an exploratory Phase I/Ib study. And AstraZeneca will also match its anti-CTLA-4 antibody tremelimumab with Kyowa's drug in a separate combination.
AstraZeneca has signed an agreement to pick up Almirall's respiratory business for up to $2.1 billion, hoping to shoulder its way to the front of a blockbuster market for COPD treatments.
After Sarepta Therapeutics' former head scientist blamed his swift ouster on "serious disagreements" with CEO Chris Garabedian, the company has moved to limit its chief executive's power, according to a report, especially when it comes to meetings with the FDA over the biotech's much-scrutinized lead drug.
Bracing for an expensive round of late-stage studies and potential drug launches as it ramps up work on a slate of new biosimilars, Amgen reported Tuesday evening that it plans to trim up to 15% of the company's workforce, shutting down facilities in Colorado and Washington state as it slashes up to 2,900 staffers.
Quark Pharmaceuticals' gene-silencing treatment for kidney transplant complications missed its primary endpoint in a Phase II trial, possibly jeopardizing a deal with Novartis worth up to $680 million.
Looking to share some of the spotlight focused on the immuno-oncology arena, Merck Serono says it has launched a mid-stage study of MSB0010718C, an anti-PD-L1 antibody.
With investors focused almost exclusively on earnings and R&D programs today, Merck quietly managed to slip in news of a setback in its quarterly report, noting that the FDA has rejected its marketing application for the fertility treatment corifollitropin alfa.
Months after a swift exit from Pfizer's highest ranks, Amy Schulman has made her next move, joining high-profile biotech investor Polaris as a venture partner
Three Big Pharma companies have helped come up with some seed money to start growing the first crop of biotechs in New York. Pfizer, Eli Lilly and J&J all chipped in to a $51 million fund from Accelerator Corp., which will now expand on the work it's been doing in Seattle to the East Side of Manhattan, recruiting upstarts to join investigators at the Alexandria Center for Life Science.